By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting originating from Chiba, Japan, by NewsRx correspondents, research stated, "Cyclooxygenase-2 (COX-2) is a key enzyme of prostaglandin (PG) synthesis that has been demonstrated to be overexpressed in several types of cancers. The function of COX-2 in tumor progression has been recently elucidated."
Our news editors obtained a quote from the research from Chiba University, "In tumors in which COX-2 is overexpressed, the antitumor effects are suppressed. We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity. We used the human esophageal squamous cell lines TE2 and T.Tn treated with celecoxib and 5-FU/radiation, after which cell viability assays were performed. Changes in the expressions of dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT) mRNA and PGE2 were also measured. In addition, apoptotic changes, and the invasion and migration activity in both the celecoxib and 5-FU treated cells were evaluated. The experiments showed that T.Tn and TE2 proliferation was strongly inhibited by the combination of 5-FU/radiation and the COX-2 inhibitor. Inhibiting the COX-2 activity induced a reduction in PGE2 levels in TE2/T.Tn cells. Following treatment with the COX-2 inhibitor and 5-FU, the OPRT expression was upregulated and the DPD expression was downregulated in the resistant cells. In addition, the combination treatment with the COX-2 inhibitor and 5-FU markedly inhibited both the cell invasion and migration activity."
According to the news editors, the research concluded: "Therefore, COX-2 inhibitors can be useful enhancers of antitumor drugs and radiotherapy for ESCC."
For more information on this research see: A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. International Journal of Oncology, 2014;44(4):1146-1152. International Journal of Oncology can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Drugs and Therapies).
The news editors report that additional information may be obtained by contacting G. Yusup, Chiba University, Dept. of Otorhinolaryngol, Grad Sch Med, Chiba 2608670, Japan. Additional authors for this research include Y. Akutsu, M. Mutallip, W. Qin, X. Hu, A. Komatsu-Akimoto, I. Hoshino, N. Hanari, M. Mori, N. Akanuma, Y. Isozaki and H. Matsubara.
Keywords for this news article include: Asia, Antiinflammatory, Chiba, Japan, COX-2, Oncology, Chemotherapy, Radiotherapy, Drugs and Therapies, Squamous Cell Carcinoma, Cyclooxygenase Inhibitors, Cyclooxygenase 2 Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC